Its an oligopoly, with Novo and Eli Lilly dominating the GLP-1 space and, alongside Sanofi, holding sway in insulins
It was the scale and potential size of the compounding required to service their database of patients that made the regulators really take notice
By addressing both weight and hormone levels, semaglutide and TRT may create a positive cycle where improved health makes it easier to achieve long-term wellness goals
While irritability is not listed as a common side effect in clinical trials, some patients do experience mood changes
She's also the founder of Hydration Bar MD, a physician-led platform focused on preventive wellness and evidence-based hydration
Compared with DPP-4i users, GLP-1 RA users were younger (mean age 56.1 vs 62.3 years), had a higher body mass index (36.5 vs 32.1 kg/m), and were less likely to be male (45.2% vs 50.4%)